(VIANEWS) – The Market ended the session with ADOCIA (ADOC.PA) jumping 9.74% to €9.24 on Wednesday, following the last session’s upward trend. CAC 40 jumped 0.69% to €8,131.41, after three consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
ADOCIA’s last close was €8.42, 47.9% under its 52-week high of €16.16.
About ADOCIA
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ADOCIA has a trailing twelve months EPS of €-1.9.
Yearly Top and Bottom Value
ADOCIA’s stock is valued at €9.24 at 22:30 EST, way below its 52-week high of €16.16 and way above its 52-week low of €2.74.
More news about ADOCIA (ADOC.PA).
